Status: Open Not Enrolling
Investigator: Shilpan Shah
Study Coordinator:
Phone:
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of th ... Read more >
Status: Enrolling
Investigator: Siddhartha Ganguly
Study Coordinator: Danielle Sewall
Phone: 346.238.2674
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab i ... Read more >
Status: Enrolling
Investigator: Siddhartha Ganguly
Study Coordinator: Britney Nguyen
Phone: 713.441.0685
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexametha ... Read more >
Status: Open Not Enrolling
Investigator: Shilpan Shah
Study Coordinator:
Phone:
The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants may or may not have already had treatment for their cancer. Participation could last up to six y ... Read more >
Status: Open Not Enrolling
Investigator: Shilpan Shah
Study Coordinator: Danielle Sewall
Phone: 346.238.2674
This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP- binding site TKI with discontinuation due to treatment failure, warning or intolerance. (2L patient cohort) ... Read more >
Status: Enrolling
Investigator: Siddhartha Ganguly
Study Coordinator: Britney Nguyen
Phone: 713.441.0685
This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell [CAR-T] therapy) for multiple myeloma. The ... Read more >
Status: Enrolling
Investigator: Siddhartha Ganguly
Study Coordinator: Danielle Sewall
Phone: 346.238.2674
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). ... Read more >
Status: Open Not Enrolling
Investigator: Siddhartha Ganguly
Study Coordinator: Danielle Grbavac
Phone: 346.238.4456
A phase 1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma. ... Read more >
Status: Enrolling
Investigator: Sai ravi kiran Pingali
Study Coordinator: Danielle Grbavac
Phone: 346.238.4456
This is a Phase IB/II trial that will investigate the safety, tolerability and efficacy of combination therapy using All-Trans Retinoic Acid (ATRA) with Carfilzomib based therapies in plasma cell myeloma also commonly referred as Multiple Myelom ... Read more >
Status: Open Not Enrolling
Investigator: Sai ravi kiran Pingali
Study Coordinator: Natolie Hamilton
Phone: 469.267.9275
This is a laboratory-based study supported by NIH funding. It is aimed to explore the therapeutic effects of novel molecules or antigens to treat hematologic diseases. In order to complete these studies, samples including peripheral blood, bone ... Read more >
Status: Enrolling
Investigator: Shilpan Shah
Study Coordinator: Danielle Grbavac
Phone: 346.238.4456
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with ... Read more >